|
Clinical characteristics of patients in NNRTI and PI group. |
|||
| Characteristics |
NNRTI N = 85 |
PI N = 14 |
P-value |
|
|
|||
| Age, mean ± SD, years |
40.6 ± 8.8 |
40.7 ± 10.9 |
0.776 |
| Gender, number (%) |
0.993 |
||
| Male |
38 (45) |
7 (50) |
|
| Female |
47 (55) |
7 (50) |
|
| Duration of HIV diagnosis, median (IQR), months |
65 (47–94) |
72 (47–109) |
0.788 |
| History of OIs, number (%) |
10 (12) |
2 (14) |
0.992 |
| HBV co-infection, number (%) |
6 (7) |
1 (7) |
0.957 |
| HCV co-infection, number (%) |
3 (4) |
0 (0) |
0.451 |
| NRTI backbone in HAART prior to TI, number (%) |
0.480 |
||
| - Stavudine + lamivudine |
43 (51) |
7 (50) |
|
| - Zidovudine + lamivudine |
35 (41) |
5 (36) |
|
| - Zidovudine + didanosine |
4 (5) |
2 (14) |
|
| - Didanosine + lamivudine |
3 (3) |
0 (0) |
|
| Duration of HAART prior to TI, median (IQR), months |
46 (36–64) |
59 (37–76) |
0.968 |
| Nadir CD4 cell count, median (IQR), cells/mm3 |
147 (57–215) |
217 (63–345) |
0.186 |
| Baseline CD4 cell counts at TI, median (IQR), cells/mm3 |
530 (441–657) |
586 (381–747) |
0.924 |
|
OIs = opportunistic infections, HBV = hepatitis B virus, HCV = hepatitis C virus | |||
Sungkanuparph et al. AIDS Research and Therapy 2007 4:26 doi:10.1186/1742-6405-4-26 |
|||